Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria: * Male or female between the ages of 18 and 85 with clinical diagnosis of ALS * Forced Vital Capacity (FVC) \> 60% of predicted * Less than 3 years of ALS since the onset of the first symptom with clinical evidence of limb muscle atrophy and weakness. * Subjects taking Riluzole must have been at a stable dose for at least 30 days with no evidence of toxicity * Female of childbearing potential and male of child-creating potential must agree to use a medically acceptable physical barrier (condom, diaphragm, and cervical cap) through the treatment phase and for at least 30 days after the last study treatment. Exclusion Criteria: * Women who are pregnant or currently breast-feeding * Dependent upon invasive or non-invasive artificial ventilation * Patients with bulbar onset ALS or with other active neuromuscular/ neurodegenerative diseases. * Type 1 or Type 2 diabetes. * Evidence of chronic or active heart, liver, kidney, or lung diseases, or Age-related macular degeneration. * Current or history of known immune or immunodeficiency disorders * Patients with cognitive impairment with significant decision making incapacity, or major depression, or schizophrenia, or dementia (e.g. Alzheimer's disease). * Malignancy or history of malignancy, except it has been in complete remission for at least 5 years * Pre-cancerous conditions (e.g. Barrett's Esophagus, dysplasias) or benign tumors which have the potential for significant growth due to VEGF stimulation.